Surveillance in stage i nonseminomatous germ cell tumours of the testis

BJU International

Volumn 104, Issue 9 B, 2009, Pages 1351-1356

  Zuniga, Alvaro ^a   Kakiashvili, David ^a   Jewett, Michael A S ^a,b  

^a Uro Oncology Fellowship Program   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BLEOMYCIN; CHORIONIC GONADOTROPIN; CISPLATIN; ETOPOSIDE; LACTATE DEHYDROGENASE; TUMOR MARKER;

CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER RELAPSE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DRUG MEGADOSE; FOLLOW UP; HUMAN; LYMPH NODE DISSECTION; NON SEMINOMATOUS GERMINOMA; ORCHIECTOMY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; RECURRENCE RISK; REVIEW; SURVIVAL RATE;

ADOLESCENT; ADULT; CHEMOTHERAPY, ADJUVANT; HUMANS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, GERM CELL AND EMBRYONAL; RISK FACTORS; TESTICULAR NEOPLASMS; YOUNG ADULT;

EID: 70350461867     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2009.08858.x     Document Type: Review

References (69)

1. Ries LA, Melbert D, Krapcho M et al. eds. SEER Cancer Statistics Review, 1975-2005. National Cancer Institute, Bethesda, MD, 2008
2. Office for National Statistics Mortality Statistics. Cause. England and Wales, 2006. Available at: http://info.cancerresearchuk.org/cancerstats/types/ testis/?a=5441. Accessed March 2009
3. Office for National Statistics Cancer Statistics registrations. Registrations of cancer diagnosed in England. Series MB1. No. 35 2005. Available at: http://info.cancerresearchuk.org/cancerstats/types/testis/?a=5441. Accessed March 2009
4. Cancer Incidence Mortality and Prevalence Worldwide. Estimates 2002. Available at: http://info.cancerresearchuk.org/cancerstats/types/testis/?a=5441. Accessed March 2009
5. Warde P, Jewett MA. Surveillance for stage I testicular seminoma. Is it a good option? Urol Clin North Am 1998 25 : 425 433
6. Sternberg CN. The management of stage I testis cancer. Urol Clin North Am 1998 25 : 435 449
7. Groll RJ, Warde P, Jewett MA. A comprehensive systematic review of testicular germ cell tumor surveillance. Crit Rev Oncol Hematol 2007 64 : 182 197
8. Krege S, Beyer J, Souchon R et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol 2008 53 : 478 496
9. Read G, Stenning SP, Cullen MH et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. Medical Research Council Testicular Tumors Working Party. J Clin Oncol 1992 10 : 1762 1768
10. Spermon JR, Roeleveld TA, van der Poel HG et al. Comparison of surveillance and retroperitoneal lymph node dissection in Stage I nonseminomatous germ cell tumors. Urology 2002 59 : 923 929
11. Choueiri TK, Stephenson AJ, Gilligan T, Klein EA. Management of clinical stage I nonseminomatous germ cell testicular cancer. Urol Clin North Am 2007 34 : 137 148 (abstract viii)
12. Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R. Primary retroperitoneal lymph node dissection in clinical stage A non-seminomatous germ cell testis cancer. Review of the Indiana University experience 1965-89. Br J Urol 1993 71 : 326 335
13. Stephenson AJ, Bosl GJ, Motzer RJ et al. Retroperitoneal lymph node dissection for nonseminomatous germ cell testicular cancer: impact of patient selection factors on outcome. J Clin Oncol 2005 23 : 2781 2788
14. Jewett MA. Nerve-sparing technique for retroperitoneal lymphadenectomy in testis cancer. Urol Clin North Am 1990 17 : 449 456
15. Albers P, Siener R, Kliesch S et al. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J Clin Oncol 2003 21 : 1505 1512
16. de Bruin MJ, Oosterhof GO, Debruyne FM. Nerve-sparing retroperitoneal lymphadenectomy for low stage testicular cancer. Br J Urol 1993 71 : 336 339
17. Donohue JP, Foster RS. Retroperitoneal lymphadenectomy in staging and treatment. The development of nerve-sparing techniques. Urol Clin North Am 1998 25 : 461 468
18. Jewett MA, Kong YS, Goldberg SD et al. Retroperitoneal lymphadenectomy for testis tumor with nerve sparing for ejaculation. J Urol 1988 139 : 1220 1224
19. Peckham MJ, Barrett A, Husband JE, Hendry WF. Orchidectomy alone in testicular stage I non-seminomatous germ-cell tumours. Lancet 1982 2 : 678 680
20. Colls BM, Harvey VJ, Skelton L et al. Late results of surveillance of clinical stage I nonseminoma germ cell testicular tumours: 17 years' experience in a national study in New Zealand. BJU Int 1999 83 : 76 82
21. Daugaard G, Petersen PM, Rorth M. Surveillance in stage I testicular cancer. APMIS 2003 111 : 76 83
22. Francis R, Bower M, Brunstrom G et al. Surveillance for stage I testicular germ cell tumours: results and cost benefit analysis of management options. Eur J Cancer 2000 36 : 1925 1932
23. Gels ME, Hoekstra HJ, Sleijfer DT et al. Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience. J Clin Oncol 1995 13 : 1188 1194
24. Nicolai N, Pizzocaro G. A surveillance study of clinical stage I nonseminomatous germ cell tumors of the testis: 10-year followup. J Urol 1995 154 : 1045 1049
25. Oliver RT, Ong J, Shamash J et al. Long-term follow-up of Anglian Germ Cell Cancer Group surveillance versus patients with Stage 1 nonseminoma treated with adjuvant chemotherapy. Urology 2004 63 : 556 561
26. Sharir S, Jewett MA, Sturgeon JF et al. Progression detection of stage I nonseminomatous testis cancer on surveillance: implications for the followup protocol. J Urol 1999 161 : 472 475
27. Sogani PC, Perrotti M, Herr HW, Fair WR, Thaler HT, Bosl G. Clinical stage I testis cancer: long-term outcome of patients on surveillance. J Urol 1998 159 : 855 858
28. Albers P. Management of stage I testis cancer. Eur Urol 2007 51 : 34 43
29. Freedman LS, Parkinson MC, Jones WG et al. Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet 1987 2 : 294 298
30. Cullen MH, Stenning SP, Parkinson MC et al. Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report. J Clin Oncol 1996 14 : 1106 1113
31. Klepp O, Dahl O, Flodgren P et al. Risk-adapted treatment of clinical stage 1 non-seminoma testis cancer. Eur J Cancer 1997 33 : 1038 1044
32. Ondrus D, Hornak M. Orchiectomy alone for clinical stage I nonseminomatous germ cell tumors of the testis (NSGCTT): a minimum follow-up period of 5 years. Tumori 1994 80 : 362 364
33. Pont J, Albrecht W, Postner G, Sellner F, Angel K, Holtl W. Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol 1996 14 : 441 448
34. Alexandre J, Fizazi K, Mahe C et al. Stage I non-seminomatous germ-cell tumours of the testis: identification of a subgroup of patients with a very low risk of relapse. Eur J Cancer 2001 37 : 576 582
35. Heidenreich A, Sesterhenn IA, Mostofi FK, Moul JW. Prognostic risk factors that identify patients with clinical stage I nonseminomatous germ cell tumors at low risk and high risk for metastasis. Cancer 1998 83 : 1002 1011
36. Hermans BP, Sweeney CJ, Foster RS, Einhorn LE, Donohue JP. Risk of systemic metastases in clinical stage I nonseminoma germ cell testis tumor managed by retroperitoneal lymph node dissection. J Urol 2000 163 : 1721 1724
37. Nicolai N, Miceli R, Artusi R, Piva L, Pizzocaro G, Salvioni R. A simple model for predicting nodal metastasis in patients with clinical stage I nonseminomatous germ cell testicular tumors undergoing retroperitoneal lymph node dissection only. J Urol 2004 171 : 172 176
38. Roeleveld TA, Horenblas S, Meinhardt W, van de Vijver M, Kooi M, ten Bokkel Huinink WW. Surveillance can be the standard of care for stage I nonseminomatous testicular tumors and even high risk patients. J Urol 2001 166 : 2166 2170
39. Sweeney CJ, Hermans BP, Heilman DK, Foster RS, Donohue JP, Einhorn LH. Results and outcome of retroperitoneal lymph node dissection for clinical stage I embryonal carcinoma - predominant testis cancer. J Clin Oncol 2000 18 : 358 362
40. Vergouwe Y, Steyerberg EW, Eijkemans MJ, Albers P, Habbema JD. Predictors of occult metastasis in clinical stage I nonseminoma: a systematic review. J Clin Oncol 2003 21 : 4092 4099
41. Maroto P, Garcia del Muro X, Aparicio J et al. Multicentre risk-adapted management for stage I non-seminomatous germ cell tumours. Ann Oncol 2005 16 : 1915 1920
42. Raghavan D, Colls B, Levi J et al. Surveillance for stage I non-seminomatous germ cell tumours of the testis: the optimal protocol has not yet been defined. Br J Urol 1988 61 : 522 526
43. Rorth M, Jacobsen GK, von der Maase H et al. Surveillance alone versus radiotherapy after orchiectomy for clinical stage I nonseminomatous testicular cancer. Danish Testicular Cancer Study Group. J Clin Oncol 1991 9 : 1543 1548
44. Sturgeon JF, Jewett MA, Alison RE et al. Surveillance after orchidectomy for patients with clinical stage I nonseminomatous testis tumors. J Clin Oncol 1992 10 : 564 568
45. Divrik RT, Akdogan B, Ozen H, Zorlu F. Outcomes of surveillance protocol of clinical stage I nonseminomatous germ cell tumors-is shift to risk adapted policy justified? The J Urol 2006 176 : 1424 1429
46. Atsu N, Eskicorapci S, Uner A et al. A novel surveillance protocol for stage I nonseminomatous germ cell testicular tumours. BJU Int 2003 92 : 32 5
47. Amato RJ, Ro JY, Ayala AG, Swanson DA. Risk-adapted treatment for patients with clinical stage I nonseminomatous germ cell tumor of the testis. Urology 2004 63 : 144 148
48. Ondrus D, Matoska J, Belan V, Kausitz J, Goncalves F, Hornak M. Prognostic factors in clinical stage I nonseminomatous germ cell testicular tumors: rationale for different risk-adapted treatment. Eur Urol 1998 33 : 562 566
49. Hao D, Seidel J, Brant R et al. Compliance of clinical stage I nonseminomatous germ cell tumor patients with surveillance. J Urol 1998 160 : 768 771
50. Fossa SD, Aass N, Winderen M, Bormer OP, Olsen DR. Long-term renal function after treatment for malignant germ-cell tumours. Ann Oncol 2002 13 : 222 228
51. Meinardi MT, Gietema JA, van der Graaf WT et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000 18 : 1725 1732
52. Sagstuen H, Aass N, Fossa SD et al. Blood pressure and body mass index in long-term survivors of testicular cancer. J Clin Oncol 2005 23 : 4980 4990
53. Strumberg D, Brugge S, Korn MW et al. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol 2002 13 : 229 236
54. Bohlen D, Burkhard FC, Mills R, Sonntag RW, Studer UE. Fertility and sexual function following orchiectomy and 2 cycles of chemotherapy for stage I high risk nonseminomatous germ cell cancer. J Urol 2001 165 : 441 444
55. Brydoy M, Fossa SD, Klepp O et al. Paternity following treatment for testicular cancer. J Natl Cancer Inst 2005 97 : 1580 1588
56. DeSantis M, Albrecht W, Holtl W, Pont J. Impact of cytotoxic treatment on long-term fertility in patients with germ-cell cancer. Int J Cancer 1999 83 : 864 865
57. Hartmann JT, Albrecht C, Schmoll HJ, Kuczyk MA, Kollmannsberger C, Bokemeyer C. Long-term effects on sexual function and fertility after treatment of testicular cancer. Br J Cancer 1999 80 : 801 807
58. Bokemeyer C, Schmoll HJ. Secondary neoplasms following treatment of malignant germ cell tumors. J Clin Oncol 1993 11 : 1703 1709
59. Travis LB, Curtis RE, Storm H et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst 1997 89 : 1429 1439
60. Travis LB, Fossa SD, Schonfeld SJ et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005 97 : 1354 1365
61. Huddart RA, Norman A, Shahidi M et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003 21 : 1513 23
62. Kollmannsberger C, Beyer J, Droz JP et al. Secondary leukemia following high cumulative doses of etoposide in patients treated for advanced germ cell tumors. J Clin Oncol 1998 16 : 3386 3391
63. Stephenson AJ, Sheinfeld J. Management of patients with low-stage nonseminomatous germ cell testicular cancer. Curr Treat Options Oncol 2005 6 : 367 377
64. Albers P, Siener R, Krege S et al. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol 2008 26 : 2966 2972
65. Berrington de Gonzalez A, Darby S. Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries. Lancet 2004 363 : 345 351
66. Brenner DJ, Elliston CD. Estimated radiation risks potentially associated with full-body CT screening. Radiology 2004 232 : 735 738
67. Rustin GJ, Mead GM, Stenning SP et al. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197 - the National Cancer Research Institute Testis Cancer Clinical Studies Group. J Clin Oncol 2007 25 : 1310 1315
68. Segal R. Surveillance programs for stage I nonseminomatous germ cell tumors of the testis. Urol Oncol 2006 24 : 68 74
69. Ernst DS, Brasher P, Venner PM et al. Compliance and outcome of patients with stage 1 non-seminomatous germ cell tumors (NSGCT) managed with surveillance programs in seven Canadian centres. Can J Urol 2005 12 : 2575 2580